地塞米松缓释剂治疗糖尿病性黄斑水肿的研究进展  

Research progress of Dexamethasone sustained release in the treatment of diabetic macular edema

作　　者：薛媛媛 陈晓隆[1] Yuan-Yuan Xue;Xiao-Long Chen(Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang 110001, Liaoning Province, China)

机构地区：[1]中国医科大学附属盛京医院眼科,中国辽宁省沈阳市110001

出　　处：《国际眼科杂志》2021年第9期1543-1547,共5页International Eye Science

基　　金：国家自然科学基金项目(No.81570866)。

摘　　要：糖尿病性黄斑水肿(DME)是糖尿病患者视力丧失甚至失明的重要原因,其治疗方案多种多样,主要包括抗血管内皮生长因子、曲安奈德及激光光凝等,均具有较好的疗效,但也存在各自的局限性。近年来,地塞米松缓释剂作为一种新的治疗方案给其他治疗反应欠佳的DME患者带来了希望,同时具有疗效佳、持续时间长、安全性可接受及患者耐受性良好等优点,使其成为了目前的研究热点。本文就地塞米松缓释剂的药理特性、治疗DME的临床研究及适用条件进行阐述。Diabetic macular edema(DME)is the foremost cause of vision impairment and even blindness in patients with diabetes mellitus.Nowadays,the approach in the treatment of DME involves laser photocoagulation,intravitreal injections of anti-VEGF agents or triamcinolone acetonide.However,they still have some limitations.In recent years,dexamethasone intravitreal implant,as a new treatment option,has brought therapeutic hope to DME patients who have poor response to other methods.Meanwhile,it has the advantages of good clinical efficacy,long duration,acceptable safety and good patient tolerability.In this paper,the research advances in dexamethasone intravitreal implant for DME are described.

关 键 词：糖尿病性黄斑水肿 地塞米松 缓释系统 

分 类 号：R58[医药卫生—内分泌]